Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

NCT02442466 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Difficulties to recruit on time the required patient population.

Conditions

Melanoma

Interventions

DRUG: Endothelin Receptor B inhibitor BQ788
DRUG: PBS

Sponsor

MelCure SA

Collaborators

[object Object]
[object Object]
[object Object]